Evidence map›Paper›PMID 26169414›Full record

ArticleAntimicrobial agents and chemotherapy2015

Inhibition of AAC(6')-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2',4'-bridged nucleic acid-NC-DNA hybrid oligomer.

Christina Lopez, Brock A Arivett, Luis A Actis, Marcelo E Tolmasky

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. CPP-PNA Conjugate-Mediated Inhibition ofInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Pathogens (Basel, Switzerland) · 2021
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Bridged Nucleic Acids Reloaded.Molecules (Basel, Switzerland) · 2019
    Review
  15. SmallFrontiers in microbiology · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Advances in therapeutic bacterial antisense biotechnology.Applied microbiology and biotechnology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Christina LopezCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, California, USA.
Brock A ArivettDepartment of Microbiology, Miami University, Oxford, Ohio, USA.
Luis A ActisDepartment of Microbiology, Miami University, Oxford, Ohio, USA.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, California, USA mtolmasky@fullerton.edu.
California State University, Fullerton · USMiami University · US

Funding

DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
NIAID NIH HHS 2R15AI047115-04NIAID NIH HHS R15 AI047115
6 · The paper itself

Abstract

Multiresistant Acinetobacter baumannii, a common etiologic agent of severe nosocomial infections in compromised hosts, usually harbors aac(6')-Ib. This gene specifies resistance to amikacin and other aminoglycosides, seriously limiting the effectiveness of these antibiotics. An antisense oligodeoxynucleotide (ODN4) that binds to a duplicated sequence on the aac(6')-Ib mRNA, one of the copies overlapping the initiation codon, efficiently inhibited translation in vitro. An isosequential nuclease-resistant hybrid oligomer composed of 2',4'-bridged nucleic acid-NC (BNA(NC)) residues and deoxynucleotides (BNA(NC)-DNA) conjugated to the permeabilizing peptide (RXR)4XB ("X" and "B" stand for 6-aminohexanoic acid and β-alanine, respectively) (CPPBD4) inhibited translation in vitro at the same levels observed in testing ODN4. Furthermore, CPPBD4 in combination with amikacin inhibited growth of a clinical A. baumannii strain harboring aac(6')-Ib in liquid cultures, and when both compounds were used as combination therapy to treat infected Galleria mellonella organisms, survival was comparable to that seen with uninfected controls.

Indexed as

Acinetobacter baumanniiAmikacinAnti-Bacterial AgentsDNAMicrobial Sensitivity TestsPeptidesAmikacinAnti-Bacterial AgentsDNAPeptides

Identifiers

PMID26169414
PMCPMC4538503
OpenAlexW1563786107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.